US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,481.74

+2.870.19%

Number of Gainers:5

Number of Losers:5

Number of Flat:1

PE:- -

High:1,502.09

Open:1,481.43

Low:1,480.76

Close:1,479.04

Loading ...

Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday

MT Newswires Live

Viatris Fails to Meet Primary Endpoint of Phase 3 Study for Blepharitis Treatment

MT Newswires Live

Viatris Shares Fall 5% Premarket After Co's Eye Therapy Fails to Meet Late-Stage Trial Goal

THOMSON REUTERS

Viatris eye therapy fails to meet late-stage trial goal

Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Quest Diagnostics Inc : UBS Cuts Target Price to $175 From $176

THOMSON REUTERS

Viatris Provides Update on Phase 3 Study of Mr-139 for Blepharitis

THOMSON REUTERS

Viatris Inc - Evaluating Next Steps for Phase 3 Program

THOMSON REUTERS

Johanna Mercier, Chief Commercial Officer, Reports Disposal of Gilead Sciences Inc. Common Shares

Gilead Sciences CFO Andrew D. Dickinson Reports Disposal of Common Shares

E-Home Household Service Holdings Ltd. Announces Potential Share Consolidation Up to 1-for-50 Ratio

Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment

Viatris (VTRS) Receives a Hold from Goldman Sachs

FDA staff raises efficacy concerns for Otsuka's PTSD combination drug

Director Jeffrey Bluestone Reports Disposal of Common Shares in Gilead Sciences Inc

Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs

MT Newswires Live

BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X Post

NY Ag James- My Office and 48 Ags Secured $202 Million From Gileadsciences - X Post

THOMSON REUTERS

Aethlon Medical Inc. Advances Hemopurifier Clinical Trial Following Positive Safety Review, Opens Enrollment for Next Patient Cohort

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1481.9083,"timestamp":1752849572058,"preClose":1479.0377,"halted":0,"volume":6443455,"delay":0,"changeRate":0.001941,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.870605,"latestTime":"07-18 10:39:33 EDT","open":1481.4298,"high":1502.089,"low":1480.762,"amount":252041350.999939,"amplitude":0.01442,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1752868800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.910864,"peRate":61.732698,"turnoverRate":0.002402,"increases":5,"decrements":5,"flats":1,"marketCap":166642958268.25,"floatMarketCap":165944400018},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1502.089,"amplitude":0.01442,"preClose":1479.0377,"low":1480.762,"pbRate":"3.910864","latestPrice":1481.7422,"volume":6444026,"delay":0,"open":1481.4298,"prevYearClose":1284.7982,"prevWeekClose":1486.2653,"prevMonthClose":1508.2938,"prevQuarterClose":1508.2938,"fiveDayClose":1486.2653,"twentyDayClose":1474.7335,"sixtyDayClose":1425.0868,"secType":"PLATE","market":"US","turnoverRate":0.002402,"peRate":61.732698,"marketCap":166642958268.25,"floatMarketCap":165944400018,"timestamp":1752849574670,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":5,"down":5,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552498191","title":"Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2552498191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552498191?lang=en_us&edition=fundamental","pubTime":"2025-07-18 21:19","pubTimestamp":1752844764,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher pre-bell Friday as the Health Care Select Sector SPDR Fund  was slightly advancing and the iShares Biotechnology ETF  was up 0.4% recently.Viatris  shares were down more than 3% after the company said a phase 3 study evaluating the efficacy and safety of MR-139 ophthalmic ointment in subjects with blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.Telomir Pharmaceuticals  shares were up more than 153% after the company said its lead candidate Telomir-1 may help restore a tumor suppressor in human prostate cancer cells.Sarepta Therapeutics  shares were down 25% following reports of another patient death in the company's gene therapy trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4583","BK4585","BK4588","IE0002141913.USD","IE0009355771.USD","BK4139","IBB","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","XLV","LU1839511570.USD","TELO","VTRS","LU2087621335.USD","BK4581","IE00B2B36J28.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2552462349","title":"Viatris Fails to Meet Primary Endpoint of Phase 3 Study for Blepharitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2552462349","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552462349?lang=en_us&edition=fundamental","pubTime":"2025-07-18 19:21","pubTimestamp":1752837663,"startTime":"0","endTime":"0","summary":"Viatris  said Friday the phase 3 study evaluating the efficacy and safety of MR-139 ophthalmic ointment in subjects with blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.The company said it is evaluating the next steps for the program, which may include a revision of the planned additional phase 3 study.Viatris shares were down 3.5% in recent Friday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VTRS","BK4585","LU2087621335.USD","BK4007","LU1839511570.USD","BK4583","BK4588"],"gpt_icon":0},{"id":"2552240464","title":"Viatris Shares Fall 5% Premarket After Co's Eye Therapy Fails to Meet Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2552240464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552240464?lang=en_us&edition=fundamental","pubTime":"2025-07-18 19:06","pubTimestamp":1752836766,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nL4N3TF0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1839511570.USD","BK4588","BK4007","LU2087621335.USD","BK4585","VTRS","BK4583"],"gpt_icon":0},{"id":"2552464256","title":"Viatris eye therapy fails to meet late-stage trial goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2552464256","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552464256?lang=en_us&edition=fundamental","pubTime":"2025-07-18 19:05","pubTimestamp":1752836754,"startTime":"0","endTime":"0","summary":"Viatris eye therapy fails to meet late-stage trial goal July 18  - Viatris VTRS.O said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nL4N3TF0VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4583","BK4585","BK4588","LU1839511570.USD","LU2087621335.USD","VTRS"],"gpt_icon":0},{"id":"2552464452","title":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2552464452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552464452?lang=en_us&edition=fundamental","pubTime":"2025-07-18 18:59","pubTimestamp":1752836361,"startTime":"0","endTime":"0","summary":"Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis. Viatris Inc., a global healthcare company, has announced the results of several key clinical trials. The company reported positive top-line results from its Phase 3 LYNX-2 trial of MR-142, aimed at keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. Additionally, Viatris shared positive outcomes from its second pivotal Phase 3 VEGA-3 trial of MR-141, focused on treating presbyopia. However, the Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing. Viatris is currently evaluating the next steps for the MR-139 Phase 3 program, which may include revising the planned additional study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL1XjCnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4583","BK4585","BK4588","LU1839511570.USD","LU2087621335.USD","VTRS"],"gpt_icon":0},{"id":"2552649944","title":"Quest Diagnostics Inc : UBS Cuts Target Price to $175 From $176","url":"https://stock-news.laohu8.com/highlight/detail?id=2552649944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552649944?lang=en_us&edition=fundamental","pubTime":"2025-07-18 18:59","pubTimestamp":1752836358,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nAZN47FL0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1854103824.USD","BK4585","LU1854104046.USD","BK4588","BK4583","BK4567","BK4196","DGX"],"gpt_icon":0},{"id":"2552960464","title":"Viatris Provides Update on Phase 3 Study of Mr-139 for Blepharitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2552960464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552960464?lang=en_us&edition=fundamental","pubTime":"2025-07-18 18:59","pubTimestamp":1752836342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nTUABRCC7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4588","LU1839511570.USD","BK4585","VTRS","LU2087621335.USD","BK4583"],"gpt_icon":0},{"id":"2552046499","title":"Viatris Inc - Evaluating Next Steps for Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2552046499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552046499?lang=en_us&edition=fundamental","pubTime":"2025-07-18 18:59","pubTimestamp":1752836342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nTUABRCC7Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","VTRS","LU1839511570.USD","BK4007","BK4585","BK4588","BK4583"],"gpt_icon":0},{"id":"2552173426","title":"Johanna Mercier, Chief Commercial Officer, Reports Disposal of Gilead Sciences Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2552173426","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552173426?lang=en_us&edition=fundamental","pubTime":"2025-07-17 05:45","pubTimestamp":1752702333,"startTime":"0","endTime":"0","summary":"Johanna Mercier, the Chief Commercial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL6ppDlx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","SG9999015952.SGD","LU1839511570.USD","BK4568","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU0289739699.SGD","BK4139","LU1430594728.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1571399168.USD","BK4550","SG9999015978.USD","LU0234570918.USD","SG9999015945.SGD","LU0823416689.USD","IE00B19Z3581.USD","LU0889565916.HKD","SG9999015986.USD","BK4566","LU1674673428.USD","LU2089984988.USD","LU1674673691.USD","LU2087621335.USD","IE00B3T34201.USD","BK4588","GILD","LU2468319806.SGD","BK4583","LU1066051498.USD","BK4585","BK4532","LU0320765992.SGD","BK4578","LU1778281490.HKD","LU0109394709.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2552731021","title":"Gilead Sciences CFO Andrew D. Dickinson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2552731021","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552731021?lang=en_us&edition=fundamental","pubTime":"2025-07-17 05:42","pubTimestamp":1752702121,"startTime":"0","endTime":"0","summary":"Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL5gjqQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","IE00BSNM7G36.USD","SG9999015945.SGD","BK4585","LU1585245621.USD","IE00BKVL7J92.USD","LU2087621335.USD","IE00B19Z3581.USD","LU2324357040.USD","BK4568","LU1839511570.USD","IE00B3T34201.USD","LU1674673691.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4532","IE00B7SZLL34.SGD","LU0109394709.USD","SG9999015986.USD","BK4566","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU0234570918.USD","SG9999015978.USD","LU0058720904.USD","IE0002270589.USD","BK4578","SG9999015952.SGD","BK4139","BK4583","LU0320765992.SGD","BK4550","LU1778281490.HKD","BK4588","LU1430594728.SGD","LU1066051498.USD","LU0823416689.USD","LU1571399168.USD","LU2468319806.SGD","GILD","LU2089984988.USD"],"gpt_icon":0},{"id":"2552178168","title":"E-Home Household Service Holdings Ltd. Announces Potential Share Consolidation Up to 1-for-50 Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2552178168","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552178168?lang=en_us&edition=fundamental","pubTime":"2025-07-17 04:16","pubTimestamp":1752696965,"startTime":"0","endTime":"0","summary":"E-Home Household Service Holdings Ltd. has announced plans for a share consolidation, to be considered at an extraordinary general meeting on July 28, 2025. The proposed consolidation will involve a ratio between one-for-two and one-for-fifty, with the exact ratio to be determined by the company's Board of Directors within 180 days following the resolution. The consolidation aims to streamline the company's share structure, with measures in place to handle fractional entitlements resulting from the process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. E-Home Household Service Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL1lFKhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EJH","BK4192","BK4583"],"gpt_icon":0},{"id":"2552124987","title":"Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2552124987","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552124987?lang=en_us&edition=fundamental","pubTime":"2025-07-17 00:13","pubTimestamp":1752682421,"startTime":"0","endTime":"0","summary":"Gilead Sciences (($GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-advances-in-triple-negative-breast-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gilead-sciences-advances-in-triple-negative-breast-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0234570918.USD","BK4566","LU1778281490.HKD","LU0823416689.USD","LU1674673691.USD","LU2087621335.USD","SG9999015978.USD","LU2089984988.USD","BK4585","IE00BKVL7J92.USD","LU0320765992.SGD","BK4588","LU1585245621.USD","BK4550","LU1430594728.SGD","LU1066051498.USD","SG9999015986.USD","GILD","LU1674673428.USD","SG9999015945.SGD","IE0002270589.USD","LU0889565916.HKD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999015952.SGD","BK4578","IE00B3T34201.USD","BK4532","LU1839511570.USD","LU1066053197.SGD","LU1571399168.USD","LU2468319806.SGD","BK4139","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","LU0058720904.USD","IE00BSNM7G36.USD","LU2324357040.USD","BK4568","LU0289739699.SGD","BK4583"],"gpt_icon":0},{"id":"2551126974","title":"Viatris (VTRS) Receives a Hold from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2551126974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551126974?lang=en_us&edition=fundamental","pubTime":"2025-07-16 22:15","pubTimestamp":1752675335,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst reiterated a Hold rating on Viatris yesterday and set a price target of $10.00. The company’s shares opened today at $9.00. C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/viatris-vtrs-receives-a-hold-from-goldman-sachs-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/viatris-vtrs-receives-a-hold-from-goldman-sachs-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443622.USD","BK4127","IE0004086264.USD","BK4516","BK4583","LU0742534661.SGD","LU2471134879.HKD","LU2471134523.USD","LU2471134796.USD","IE0004091025.USD","LU0048573561.USD","LU1839511570.USD","LU2237443549.SGD","BK4550","LU1868837136.USD","LU1868836757.USD","BK4585","LU0251131958.USD","LU2237443978.SGD","LU1868837300.USD","BK4533","IE0034235188.USD","LU2237443895.HKD","LU1791807156.HKD","LU1868836591.USD","LU2750360997.AUD","LU1668664300.SGD","BK4552","IE00BSNM7G36.USD","LU2750360641.GBP","LU0096364046.USD","IE00BFXG1179.USD","IE00B19Z3B42.SGD","LU1868836914.USD","LU2087621335.USD","LU1894683348.USD","IE00B19Z3581.USD","LU0061475181.USD","LU2237443465.HKD","BK4504","LU0106831901.USD","LU2471134952.CNY","LU0251142724.SGD","BK4007","BK4588","LU2237443382.USD","VTRS","IE0002270589.USD","LU1894683264.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"2551123461","title":"FDA staff raises efficacy concerns for Otsuka's PTSD combination drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2551123461","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551123461?lang=en_us&edition=fundamental","pubTime":"2025-07-16 21:10","pubTimestamp":1752671453,"startTime":"0","endTime":"0","summary":"FDA staff raises efficacy concerns for Otsuka's PTSD combination drug July 16  - The U.S. Food and Drug Administration's staff reviewers on Wednesday raised efficacy concerns over Otsuka Pharma's 4578.T combination treatment for adults with post-traumatic stress disorder , citing inconsistent trial results and a modest treatment effect that may not be clinically meaningful.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL4N3TD125:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","VTRS","LU2087621335.USD","BK4583","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"2551194413","title":"Director Jeffrey Bluestone Reports Disposal of Common Shares in Gilead Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194413","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551194413?lang=en_us&edition=fundamental","pubTime":"2025-07-16 03:59","pubTimestamp":1752609597,"startTime":"0","endTime":"0","summary":"Jeffrey Bluestone, a Director at Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL6zSKpL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU1674673428.USD","BK4588","IE00B19Z3B42.SGD","BK4568","LU1430594728.SGD","LU1674673691.USD","IE00BSNM7G36.USD","SG9999015978.USD","LU0109394709.USD","BK4550","SG9999015945.SGD","IE00B19Z3581.USD","LU2468319806.SGD","LU0234570918.USD","LU0058720904.USD","SG9999015986.USD","BK4139","BK4566","BK4532","BK4583","BK4585","IE0002270589.USD","IE00BZ1G4Q59.USD","LU1778281490.HKD","LU2087621335.USD","LU0289739699.SGD","IE00B3T34201.USD","LU1585245621.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU0320765992.SGD","LU1066053197.SGD","LU0823416689.USD","LU2089984988.USD","SG9999015952.SGD","LU1571399168.USD","LU2324357040.USD","GILD","LU1839511570.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2551194848","title":"Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194848","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551194848?lang=en_us&edition=fundamental","pubTime":"2025-07-16 03:04","pubTimestamp":1752606251,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) has agreed to pay $202 million to settle claims that it violated US anti-kickback laws through its HIV drug speaker programs, according to a Tuesday statement by New York Attorn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU1066053197.SGD","BK4550","LU2324357040.USD","LU1066051498.USD","SG9999015952.SGD","LU0109394709.USD","LU1778281490.HKD","GILD","LU0289739699.SGD","BK4532","LU2089984988.USD","SG9999015945.SGD","BK4588","IE00B19Z3581.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1674673691.USD","BK4578","LU0889565916.HKD","LU0058720904.USD","LU1571399168.USD","BK4585","LU0234570918.USD","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","IE00B3T34201.USD","SG9999015978.USD","BK4568","BK4566","LU1430594728.SGD","IE00BKVL7J92.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4583"],"gpt_icon":0},{"id":"2551196293","title":"BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X Post","url":"https://stock-news.laohu8.com/highlight/detail?id=2551196293","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551196293?lang=en_us&edition=fundamental","pubTime":"2025-07-16 00:30","pubTimestamp":1752597003,"startTime":"0","endTime":"0","summary":"BRIEF-NY AG James- My Office And 48 AGS Secured $202 Million From Gilead Sciences - X PostJuly 15 (Reuters) - Gilead Sciences Inc GILD.O:NY AG JAMES- MY OFFICE AND 48 AGS SECURED $202 MILLION FROM GILEADSCIENCES - X POSTSource https://tinyurl.com/ymr5t6ca ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nFWN3TC13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1066053197.SGD","BK4550","LU2324357040.USD","LU1066051498.USD","SG9999015952.SGD","LU0109394709.USD","LU1778281490.HKD","GILD","LU0289739699.SGD","BK4532","LU2089984988.USD","SG9999015945.SGD","BK4588","IE00B19Z3581.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1674673691.USD","BK4578","LU0889565916.HKD","LU0058720904.USD","LU1571399168.USD","BK4585","LU0234570918.USD","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","IE00B3T34201.USD","SG9999015978.USD","BK4568","BK4566","LU1430594728.SGD","IE00BKVL7J92.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4583"],"gpt_icon":0},{"id":"2551196281","title":"NY Ag James- My Office and 48 Ags Secured $202 Million From Gileadsciences - X Post","url":"https://stock-news.laohu8.com/highlight/detail?id=2551196281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551196281?lang=en_us&edition=fundamental","pubTime":"2025-07-16 00:30","pubTimestamp":1752597002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nFWN3TC13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2089984988.USD","LU1585245621.USD","LU2468319806.SGD","BK4550","LU2324357040.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","IE0002270589.USD","IE00B19Z3581.USD","LU0823416689.USD","SG9999015986.USD","BK4566","BK4583","IE00B7SZLL34.SGD","LU1674673428.USD","SG9999015945.SGD","LU1430594728.SGD","LU0234570918.USD","LU2087621335.USD","IE00B3T34201.USD","LU0320765992.SGD","BK4585","LU0289739699.SGD","LU0889565916.HKD","SG9999015978.USD","GILD","LU1571399168.USD","BK4578","BK4532","LU1674673691.USD","LU1066053197.SGD","IE00BSNM7G36.USD","LU1066051498.USD","BK4139","BK4568","BK4588","LU0058720904.USD","IE00BZ1G4Q59.USD","SG9999015952.SGD","LU0109394709.USD","LU1839511570.USD"],"gpt_icon":0},{"id":"2551162393","title":"Aethlon Medical Inc. Advances Hemopurifier Clinical Trial Following Positive Safety Review, Opens Enrollment for Next Patient Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2551162393","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551162393?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:03","pubTimestamp":1752581031,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. Advances Hemopurifier Clinical Trial Following Positive Safety Review, Opens Enrollment for Next Patient Cohort. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire  on July 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL6STSr1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4082","AEMD","BK4568"],"gpt_icon":0},{"id":"2551164457","title":"Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164457?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:01","pubTimestamp":1752580863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUA5XLBWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4082","AEMD","BK4568"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":77,"code":"91000000","status":"200"}]}}